At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 503 enrolled
Drug / intervention
Fluticasone Furoate/GW642444 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Double Dummy, Active Comparator, Parallel Group, Multicenter Study to Evaluate the Safety of Once-Daily Fluticasone Furoate/GW642444 Inhalation Powder for 52 Weeks in Adolescent and Adult Subjects With Asthma
In Brief
A Phase 3 clinical trial evaluating Fluticasone Furoate/GW642444 and Fluticasone propionate for Asthma. Completed, enrolled 503 participants across 47 sites in 4 countries.
Detailed Summary
The purpose of this study is to evaluate the long-term safety of fluticasone furoate/GW642444
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
CountriesGermany, Thailand, Ukraine, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartOct 2009
First PostedNov 2009
Primary CompletionMay 2011
Study CompletionMay 2011
TodayJul 2026
First PostedNov 23, 2009
Enrollment StartOct 19, 2009
Primary CompletionMay 1, 2011
Study CompletionMay 12, 2011
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 16.6 years ago
Interventions
Fluticasone Furoate/GW642444drug
Combination inhaled corticosteroid and long-acting beta2-agonist
Fluticasone propionatedrug
Inhaled corticosteroid